Patents Assigned to INSERM ( INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE)
  • Methods and pharmaceutical compositions for the treatment of cancer
    Patent number: 10894042
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: January 19, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Alain Couvineau, Valérie Gratio, Pascal Nicole, Thierry Voisin
  • Human monoclonal antibodies against orexin receptor type 1
    Patent number: 10758615
    Abstract: The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: September 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Alain Couvineau, Thierry Voisin, Pascal Nicole, Bruno Robert, Pierre Martineau, Myriam Chentouf
  • Post-translation modified cardiac troponin T as a biomarker of a risk for heart failure
    Patent number: 8986936
    Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: March 24, 2015
    Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de Rouen
    Inventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
  • Method for selectively quantifying VEGF isoforms in a biological sample and uses thereof
    Patent number: 8530162
    Abstract: The present invention pertains to a novel method for quantifying VEGF various isoforms in a biological sample, with a very high selectivity and sensitivity. It also concerns a method for establishing a diagnostic and/or a prognosis concerning a patient potentially suffering from cancer, diabetes, or cardiovascular disease, comprising a step of determining the level of at least one of the VEGF isoforms, in a biological sample from said patient.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: September 10, 2013
    Assignees: INSERM (Institut National de la Santa et de la Recherche Medicale), Assistance Publique-Hopitaux de Paris
    Inventors: Fabien Calvo, Samia Mourah, Benyoussef Naimi
  • Method for Preventing Cancer Metastasis
    Publication number: 20130029925
    Abstract: The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.
    Type: Application
    Filed: February 17, 2011
    Publication date: January 31, 2013
    Applicants: UNIVERSITE DE BRETAGNE OCCIDENTALE (U.B.O.), INSERM ( INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE), UNIVERSITE FRANCOIS-RABELAIS DE TOURS
    Inventors: Christophe Vandier, Philippe Bougnoux, Aurelie Chantome, Bernard Corbel, Alban Girault, Jean-Pierre Haelters, Virginie Joulin, Marie Potier-Cartereau, Gaelle Simon